17,261 trials
Liver Transplantation
Primary: Area Under the Concentration-time Curve From Time 0 to 24 Hours (AUC0-24) for Tacrolimus — 198.2; 193.0 ng*hr/mL
Carcinoma, Non-Small-Cell Lung
Primary: Percentage of Participants With Best Objective Response — 13.0 percentage of participants
Breast Neoplasms
Primary: Objective Response (OR) — 80.0; 75.0; 36.4 Percentage of participants
Prostate Cancer
Primary: Overall Clinical Benefit of Tarceva in CRPC. — 36 percentage of pts w/clinical benefit
HIV Infections · Sexually Transmitted Diseases
Primary: Percentage of Participants With HPV6 Antibody Development From Seronegative Status at Baseline to Seropositive Status a Month After Completion of HPV Vaccination Series…
Carcinoma, Non-Small-Cell Lung
Primary: Percentage of Participants With Best Objective Response — 0 Percentage of participants
Alcoholism
Primary: Alcohol Urge — 22.5; 19.4 units on a scale
Stroke
Primary: Volume of New FLAIR Lesions(MRI) — 915; 477 mm^3 — p=0.445
Low Bone Mass · Low Bone Mineral Density · Osteoporosis
Primary: Number of Participants With Normal/Abnormal Bone Histology — 15; 15; 15; 0 Participants
Recurrent Melanoma · Stage IV Melanoma
Primary: Tumor Response — 0; 0 participants
Kidney Transplantation
Primary: The Rate of Allograft Rejection — 0; 0 participants
Type 2 Diabetes Mellitus
Primary: Adjusted Mean Change in HbA1c Levels — -0.12; -0.10; -0.37; -0.44 percent — p=<0.0001
Carcinoma, Non-Small-Cell Lung
Primary: Objective Response (OR) as Determined by RECIST 1.0 — 62.0 percentage of participants
Raised Intraocular Pressure
Primary: Percentage Change in Mean Intra-ocular Pressure Compared With Baseline After 4 Weeks Treatment — 0.8; -0.4; -8.1; -11.0 Percentage change — p=0.822
Breast Neoplasms
Primary: Objective Response (OR) — 0 Participants with OR